Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Hedge Funds > Sarissa Capital Management > News, Interviews, and Investor Letters

Hedge Fund - Sarissa Capital Management

News, Interviews, and Investor Letters
13D Filing: Sarissa Capital Management and Emmaus Life Sciences Inc.

13D Filing: Sarissa Capital Management and Emmaus Life Sciences Inc.

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f...

Keep Reading →

April 3rd, 2018 - Hedge Funds

13D Filing: Sarissa Capital Management and Apricus Biosciences Inc. (APRI)

13D Filing: Sarissa Capital Management and Apricus Biosciences Inc. (APRI)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f...

Keep Reading →

March 23rd, 2018 - Hedge Funds

13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

Novelion Therapeutics Inc. (NASDAQ:NVLN): Alex Denner's Sarissa Capital Management filed an amended 13D. You can check out Sarissa Capital Management's latest holdings and filings here.

Keep Reading →

March 20th, 2018 - Hedge Funds

Hedge Fund and Insider Trading News: Steven Cohen, Starboard Value, Zendesk Inc (ZEN), CTI BioPharma Corp (CTIC), and More

Hedge Fund and Insider Trading News: Steven Cohen, Starboard Value, Zendesk Inc (ZEN), CTI BioPharma Corp (CTIC), and More

Just as billionaire Steven Cohen stages a comeback as a hedge fund manager, a current employee sued his Point72 Asset Management accusing it of discriminating against women and promoting a culture of ...

Keep Reading →

February 13th, 2018 - Hedge Funds Insider Trading

13D Filing: Sarissa Capital Management and Apricus Biosciences Inc. (APRI)

13D Filing: Sarissa Capital Management and Apricus Biosciences Inc. (APRI)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f...

Keep Reading →

February 6th, 2018 - Hedge Funds

13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f...

Keep Reading →

August 8th, 2017 - Hedge Funds

13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f...

Keep Reading →

July 3rd, 2017 - Hedge Funds

Hedge Fund News: Nelson Peltz, Bill Ackman, Ray Dalio

Hedge Fund News: Nelson Peltz, Bill Ackman, Ray Dalio

Peltz is that rare breed of insurgent known as "operational activists" because his track record as an operator sets him apart from "financial activists," investors from a hedge fund background who focus...

Keep Reading →

March 13th, 2017 - Hedge Funds

140 Biggest and Most Famous Activist Hedge Funds

140 Biggest and Most Famous Activist Hedge Funds

After all, activist hedge funds get most of their earnings from investing in companies and pushing them to provide more shareholder value.

Keep Reading →

February 2nd, 2017 - Hedge Funds News

Sarissa Capital Management and Aegerion Pharmaceuticals, Inc. (AEGR) Amend Nomination Agreement

Sarissa Capital Management and Aegerion Pharmaceuticals, Inc. (AEGR) Amend Nomination Agreement

In a recent filing with the US Securities and Exchange Commission, Alex Denner's Sarissa Capital Management has reported entering into an amendment to the nomination agreement with Aegerion Pharmaceuticals...

Keep Reading →

March 22nd, 2016 - Hedge Funds News

Insider Monkey Quarterly Strategy
+246.9% Insider Monkey Quarterly Strategy
+107.5% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF
200%
100%
0
Subscribe Now

Returns since its inception in May 2014 (through Feb 16th, 2024)